Discontinued — last reported Q3 '23
Products & Services · Revenue
Milestone Revenue — Revenue
This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ2 2018
Last reportedQ3 2023Oct 31, 2023
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful progress in drug development programs and the realization of contractual incentives, while a decrease may suggest delays in clinical trials or regulatory hurdles.
Detailed definition
Milestone revenue represents non-recurring payments received from collaboration or licensing partners upon the achieveme...
Peer comparison
Common in biotechnology and pharmaceutical firms that utilize licensing models, where peers often report these as 'collaboration revenue' or 'milestone payments' depending on accounting treatment.
Metric ID:
incy_segment_milestone_revenue_revenuesHistorical Data
8 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | |
|---|---|---|---|---|---|---|---|---|
| Value | $10M | $35M | $5M | $130M | $0 | $0 | $0 | $5M |
| QoQ Change | — | +250.0% | -85.7% | >999% | -100.0% | — | — | — |
| YoY Change | — | — | — | >999% | -100.0% | -100.0% | -100.0% | — |
Range$0 – $130M
CAGR-32.7%
Avg YoY Growth+225.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's milestone revenue — revenue?
- Incyte (INCY) reported milestone revenue — revenue of $5M in Q3 2023.
- What does milestone revenue — revenue mean?
- Revenue earned from partners when specific drug development or regulatory goals are achieved.